Table 1 Phosphodiesterase inhibitors assessed in clinical trials (2016–2020) [5, 25,26,27,28] (Year refers to the years in which the agent is listed on clinicaltrials.gov as being in a clinical trial)
From: New approaches to symptomatic treatments for Alzheimer’s disease
Year | Agent | PDE Target | Phase | Outcome |
|---|---|---|---|---|
2020, 2019 | BPN14770 | 4 | 2 | Synaptic, neuroprotection, anti-inflammatory |
2020, 2019, 2018, 2017, 2016 | Cilostazol | 3 | 2 | Synaptic plasticity and neuroprotection; improved circulation |
2019 | AR1001 | 5 | 2 | Synaptic plasticity and amyloid reduction |
2017, 2016 | BI 409306 | 9A | 3 | Cognitive enhancer |